Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relugolix Combination Therapy in Advanced Prostate Cancer
NCT04666129Phase 1Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Feb 2021
- Primary completion
- May 2024
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, open-label trial of relugolix in prostate cancer (PCa) and metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by Sumitomo Pharma America. Primary endpoint: Incidence of Adverse Events up to 52 weeks. Started Feb 2021; status: completed.
02
Drugs
relugolix
03
Conditions
prostate cancer (PCa)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04666129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04666129.